Brief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
28/10/2026 15:17
BRIEF-CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion Oct 28 (Reuters) - CSPC PHARMACEUTICAL GROUP LIMITED 1093.HK:
CSPC INNOVATION PHARMACEUTICAL 9M NET PROFIT ATTRIBUTABLE RMB 1.21 BILLION
9M CSPC INNOVATION PHARMA CAS OPERATING REVENUE RMB3.98 BILLION
Further company coverage: 1093.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Initiates Phase I Clinical Trial Of SYS6057 RSV Vaccine In China
Brief: Cspc Pharmaceutical Initiates Phase I/II Trial Of SYS6052 Herpes Zoster Vaccine In China
Brief: CSPC Pharmaceutical - Phase III Trial Of Prusogliptin, Dapagliflozin, Metformin Achieves Positive Topline Results
Brief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer